Values First Advisors’s Karuna Therapeutics KRTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q1
– Sell
-4,039
Closed -$1.28M – 179
2023
Q4
$1.28M Sell
4,039
-68
-2% -$13.2K 0.77% 42
2023
Q3
$694K Sell
4,107
-83
-2% -$15.6K 0.45% 68
2023
Q2
$909K Sell
4,190
-102
-2% -$21.9K 0.55% 52
2023
Q1
$780K Buy
4,292
+286
+7% +$54.7K 0.5% 59
2022
Q4
$787K Sell
4,006
-1,245
-24% -$267K 0.55% 54
2022
Q3
$1.18M Sell
5,251
-496
-9% -$100K 0.85% 39
2022
Q2
$727K Sell
5,747
-416
-7% -$47.8K 0.52% 60
2022
Q1
$781K Sell
6,163
-237
-4% -$26.7K 0.49% 62
2021
Q4
$838K Sell
6,400
-391
-6% -$50.5K 0.5% 68
2021
Q3
$831K Buy
6,791
+365
+6% +$42.1K 0.54% 61
2021
Q2
$732K Buy
6,426
+4,744
+282% +$555K 0.5% 72
2021
Q1
$202K Buy
+1,682
New +$191K 0.15% 134

Other funds holding KRTX

Values First Advisors's KRTX Position: Q1 2024 in Review

Values First Advisors sold out of Karuna Therapeutics (KRTX) in Q1 2024, closing a stake of 4,039 shares — an estimated $1.28M sold.

Values First Advisors first reported a position in KRTX in Q1 2021 and held it in 12 quarters. The position peaked at $1.28M in Q4 2023. 2 funds tracked by Wall St. Rank hold KRTX as of Q1 2024.

  • Values First Advisors reported no remaining Karuna Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Values First Advisors sold 4,039 Karuna Therapeutics shares in Q1 2024, an estimated $1.28M.
  • Values First Advisors first reported a position in Karuna Therapeutics in Q1 2021 and held it in 12 quarters.
  • Values First Advisors's Karuna Therapeutics position peaked at $1.28M in Q4 2023.
  • 2 funds tracked by Wall St. Rank held Karuna Therapeutics as of Q1 2024.

Based on Values First Advisors's 13F filing for Q1 2024, filed 23 Apr 2024.